GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Tax Provision

Noile-Immune Biotech (TSE:4893) Tax Provision : 円-2.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Tax Provision?

Noile-Immune Biotech's tax provision for the three months ended in Mar. 2024 was 円-0.6 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was 円-2.4 Mil.


Noile-Immune Biotech Tax Provision Historical Data

The historical data trend for Noile-Immune Biotech's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Tax Provision Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Provision
-5.68 -2.42 -2.42 -2.42

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Provision Get a 7-Day Free Trial Premium Member Only -0.61 -0.61 -0.61 -0.60 -0.61

Noile-Immune Biotech Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines